G. Yuan

发表

Concomitant Use of the 3-Dose Oral Pentavalent Rotavirus Vaccine With a 3-Dose Primary Vaccination Course of a Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Inactivated Polio-Haemophilus influenzae Type b Vaccine: Immunogenicity and Reactogenicity

P. van Damme, D. Koller, Penny M Heaton, 2009, The Pediatric infectious disease journal.

Concomitant Use of the Oral Pentavalent Human-Bovine Reassortant Rotavirus Vaccine and Oral Poliovirus Vaccine

K. Gottesdiener, Penny M Heaton, G. Liu, 2008, The Pediatric infectious disease journal.

Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.

W. Chung, K. Clément, I. Farooqi, 2020, The lancet. Diabetes & endocrinology.

Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in Bardet‐Biedl syndrome

J. Yanovski, M. Stewart, S. Brady, 2020, Diabetes, obesity & metabolism.

The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: Phase 3 trial design

J. Yanovski, Joan C. Han, M. Stewart, 2021, Contemporary clinical trials communications.

Effect of Setmelanotide, an MC4R Agonist, on Obesity in Bardet-Biedl Syndrome

J. Yanovski, M. Stewart, S. Brady, 2020 .

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)

R. Darouiche, F. Wagenlehner, G. Yuan, 2015, The Lancet.

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)

P. Barie, J. Solomkin, C. Eckmann, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Potential clinical treatment prospects behind the molecular mechanism of alternative lengthening of telomeres (ALT)

G. Yuan, Haolu Sun, Guijuan Chen, 2023, Journal of Cancer.

A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab (MSB0010718C) in patients with metastatic Merkel cell carcinoma.

P. Nghiem, H. Kaufman, O. Hamid, 2015 .

Clinical pharmacokinetic assessment of an anti-MAdCAM monoclonal antibody therapeutic by LC-MS/MS.

Hendrik Neubert, Musarat Kabir, Steven W. Martin, 2012, Analytical chemistry.

Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.

K. Clément, H. Dollfus, J. Argente, 2022, The lancet. Diabetes & endocrinology.

1044Efficacy of Ceftolozane/Tazobactam vs Levofloxacin in the Treatment of Complicated Urinary Tract Infections (cUTI) caused by Levofloxacin-resistant Pathogens: Results from the ASPECT-cUTI Trial

E. Goldstein, G. Sakoulas, M. Yoon, 2014, The Journal of antimicrobial chemotherapy.

ODP606 Long-term Efficacy of Setmelanotide in Patients With Bardet-Biedl Syndrome

K. Clément, P. Beales, H. Dollfus, 2022, Journal of the Endocrine Society.

Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation.

H. Youssoufian, O. Shebanova, Joyce F. Liu, 2018 .

First Dose Ranging Clinical Trial Design: More Doses? Or a Wider Range?

Naitee Ting, G. Yuan, 2014 .

Primaquine to stop transmission of falciparum malaria

G. Yuan, J. Steenbergen, Darouiche Ro, 2016 .

Efficacy and Safety Analysis of Setmelanotide As a Novel Treatment for Hypothalamic Obesity

C. Roth, Ashley H. Shoemaker, Jennifer L Miller, 2023, Endocrine Abstracts.

Impact of Setmelanotide Treatment on Reducing Hyperphagia in Pediatric and Adult Patients With Hypothalamic Obesity

C. Roth, M. Gottschalk, S. Malhotra, 2023, Endocrine Abstracts.